Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Bafna Pharmaceuticals Ltd. significantly lags behind its peers in key financial metrics, including revenue growth, profitability, and efficiency. Its negative ROE and high PE ratio indicate financial distress, making it a risky investment compared to stronger competitors in the pharmaceuticals sector.
Leading in profitability with a PE of 23.73, ROE of 16.63%, and solid revenue growth of 13.28% YoY.
Strong revenue growth (8.42% YoY) and profitability metrics (ROE of 16.13%), though it has a high PE of 87.59.
Strong overall metrics with a low PE (15.50) and high profitability (ROE of 21.76%).